Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel

Data Presentation at Society for Immunotherapy of Cancer Annual Meeting 
Supports Potential of Peregrine Pharmaceuticals' Novel
Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies 
Phosphatidylserine (PS) and CTLA-4 Targeting Antibody Combination
Stopped Tumor Growth in 100% of Animals in Preclinical Melanoma
Model; Planning Underway for Near-Term Phase I Clinical Trial
Evaluating Bavituximab and Anti-CTLA-4 Combination Immunotherapy in
Patients With Advanced Melanoma 
TUSTIN, CA -- (Marketwired) -- 11/08/13 --  Peregrine
Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the presentation
of data at the Society for Immunotherapy of Cancer (SITC) Annual
Meeting in National Harbor, Maryland being held November 7-10. The
data showed that phosphatidylserine (PS)-targeting antibodies
reactivate tumor immunity at multiple levels and that these
antibodies, when combined with an anti-CTLA-4 antibody, an
FDA-approved immunotherapy, yielded enhanced anti-tumor activity in a
pre-clinical model of melanoma. Peregrine is planning to initiate a
Phase III clinical trial in second-line non-small cell lung cancer
with its lead PS-targeting antibody bavituximab by year-end.  
In the presentation titled: "Targeting of Phosphatidylserine by
Monoclonal Antibodies Induces Innate and Specific Anti-tumor
Responses," scientists from Peregrine and The University of Texas
Southwestern Medical Center examined the anti-tumor response of a
PS-targeting antibody equivalent to bavituximab and anti-CTLA-4
combination therapy in a mouse melanoma model. Results showed that
the group (n=12) that received the combination resulted in superior
tumor growth inhibition than with either antibody alone with no
additional toxicity following multiple treatment doses. In addition,
histopathological analysis showed the combination produced more
inflammatory cell infiltration and tumor destruction than anti-CTLA-4
alone.  
"The results presented at SITC demonstrate that PS-targeting
antibodies can block PS-mediated immunosuppression while
simultaneously activating the immune system and that these effects
can greatly improve the number of subjects responding to anti-CTLA-4
immunotherapy," said Jeff T. Hutchins, Ph.D., vice president of
preclinical research at Peregrine. "We believe the encouraging
preclinical combination treatment data are due in part to the ability
of bavituximab to facilitate an increase in tumor-specific cytotoxic
T-cell activity, a function that appears to expand and broaden the
potential of immunotherapeutic agents including anti-CTLA-4 and
anti-PD-1 which prime and sustain T-cell mediated killing of tumor
cells in our pre-clinical models. We are continuing to explore these
and other immunotherapy combinations and look forward to reporting
additional results as they become available." 
In the presentation titled: "Phosphatidylserine-targeting antibody
induces M1 macrophage polarization, promotes myeloid derived
suppressor cell differentiation, boosts tumor-specific immunity,"
researchers from The University of Texas Southwestern Medical Center
showed that equivalents of bavituximab facilitated a tumor-localized
decrease in immunosuppressive cytokines and immune cells, while
inducing an increase in immunostimulatory cytokines, tumor-fighting
M1 macrophages, mature dendritic cells and tumor-specific cytotoxic
T-cells.  
"These encouraging data further support the potential of giving
bavituximab to enhance the potential of other immunotherapies such as
anti-CTLA-4 antibodies. Our goal is to now advance this combination
into clinical studies as part of our plans to obtain further proof of
concept data for novel immunotherapy combinations including
bavituximab," said Joseph Shan, MPH, vice president of clinical and
regulatory affairs at Peregrine. "Recent clinical data have shown
that immunotherapies can enhance tumor-specific T-cell responses
resulting in promising survival benefits in some patients. We believe
that bavituximab, by breaking immune tolerance in tumors and
activating both the innate and adaptive immune system, holds the
potential to allow more patients to respond to immunotherapies such
as anti-CTLA-4 antibodies that target other checkpoints in the immune
cascade. As such, we are actively working towards initiating a
clinical trial in the coming months to further investigate the
potential synergistic effects of bavituximab and an approved
immunotherapy in patients with melanoma."  
Presentation Details 
Poster #172 Targeting of Phosphatidylserine by Monoclonal Antibodies
Induces Innate and Specific Anti-tumor Responses. Jian Gong, Xianming
Huang, Van Nguyen, Richard Archer, Jeff Hutchins, Steven King, Bruce
Freimark, Peregrine Pharmaceuticals, Inc., Tustin, California,
University of Texas Southwestern Medical Center, Dallas, Texas 
When: 
 Saturday, November 9th from 6:15-7:15 PM  
Location: 
 Gaylord National Hotel & Convention Center
 Convention
Center Lower Level
 Prince George's Exhibit Hall E 
http://www.peregrineinc.com/images/stories/pdfs/sitc_172_gong.pdf  
Poster #176 Phosphatidylserine-targeting antibody induces M1
macrophage polarization, promotes myeloid derived suppressor cell
differentiation, boosts tumor-specific immunity. Xianming Huang, Yin
Yi, Gustavo Barbero, Dan Ye, Philip E. Thorpe, Department of
Pharmacology, The University of Texas Southwestern Medical Center,
Dallas, Texas  
When: 
 Saturday, November 9th from 6:15-7:15 PM  
Location:
 Gaylord
National Hotel & Convention Center
 Convention Center Lower Level 
Prince George's Exhibit Hall E 
http://www.peregrineinc.com/images/stories/pdfs/sitc_176_huang.pdf  
About Bavituximab: A Targeted Immunotherapy 
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting
monoclonal antibody that represents a new approach to treating
cancer. PS is a highly immunosuppressive molecule usually located
inside the membrane of healthy cells, but "flips" and becomes exposed
on the outside of cells that line tumor blood vessels, causing the
tumor to evade immune detection. Bavituximab targets PS and activates
the maturation of dendritic cells and cancer-fighting (M1)
macrophages leading to the development of cytotoxic T-cells that
fight solid tumors through blocking this immunosuppressive PS signal.
Bavituximab is the company's lead PS-targeting investigational
product and is currently being evaluated in several solid tumor
indications, including non-small cell lung cancer, breast cancer,
liver cancer and rectal cancer. 
About Peregrine Pharmaceuticals 
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative monoclonal antibodies in clinical trials
focused on the treatment and diagnosis of cancer. The company is
pursuing multiple clinical programs in cancer with its lead
immunotherapy candidate bavituximab and novel brain cancer agent
Cotara(R). Peregrine also has in-house cGMP manufacturing
capabilities through its wholly-owned subsidiary Avid Bioservices,
Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found at
www.peregrineinc.com. 
Safe Harbor Statement: Statements in this press release which are not
purely historical, including statements regarding Peregrine
Pharmaceuticals' intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements involve risks and uncertainties including, but not limited
to, the risk that the results from ongoing proof-of-concept studies
may not be consistent with the results published in the manuscript,
the risk that combining bavituximab with other antibodies that
enhance tumor immunity, such as an anti-PD1, anti-PD-L1, or
anti-CTLA-4, may not result in any additional benefit, and the risk
that the results from the planned Phase I clinical trial evaluating
bavituximab with anti-CTLA-4 in patients with advanced melanoma may
not be consistent with the results from the preclinical model. It is
important to note that the company's actual results could differ
materially from those in any such forward-looking statements. Factors
that could cause actual results to differ materially include, but are
not limited to, uncertainties associated with completing preclinical
and clinical trials for our technologies; the early stage of product
development; the significant costs to develop our products as all of
our products are currently in development, preclinical studies or
clinical trials; obtaining additional financing to support our
operations and the development of our products; obtaining regulatory
approval for our technologies; anticipated timing of regulatory
filings and the potential success in gaining regulatory approval and
complying with governmental regulations applicable to our business.
Our business could be affected by a number of other factors,
including the risk factors listed from time to time in our reports
filed with the Securities and Exchange Commission including, but not
limited to, our annual report on Form 10-K for the fiscal year ended
April 30, 2013 and our quarterly report on Form 10-Q for the quarter
ended July 31, 2013. The company cautions investors not to place
undue reliance on the forward-looking statements contained in this
press release. Peregrine Pharmaceuticals, Inc. disclaims any
obligation, and does not undertake to update or revise any
forward-looking statements in this press release. 
Contact: 
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals 
(800) 987-8256 
info@peregrineinc.com 
 
 
Press spacebar to pause and continue. Press esc to stop.